PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25493642-6 2014 Knockdown of alpha1 and alpha2 catalytic subunit expression of AMPK reversed the inhibitory effect produced by treatment with low concentrations of berberine on mTORC1, ERK and DNA synthesis in PDAC cells. Berberine 148-157 mitogen-activated protein kinase 1 Homo sapiens 169-172 25493642-5 2014 Furthermore, berberine dose-dependently inhibited mTORC1 (phosphorylation of S6K at Thr389 and S6 at Ser240/244) and ERK activation in PDAC cells stimulated by insulin and neurotensin or fetal bovine serum. Berberine 13-22 mitogen-activated protein kinase 1 Homo sapiens 117-120 25493642-7 2014 However, at higher concentrations, berberine inhibited mitogenic signaling (mTORC1 and ERK) and DNA synthesis through an AMPK-independent mechanism. Berberine 35-44 mitogen-activated protein kinase 1 Homo sapiens 87-90 21527846-0 2011 Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells. Berberine 65-74 mitogen-activated protein kinase 1 Homo sapiens 39-42 24905527-3 2014 RESULTS: Our results showed that berberine could inhibit LPS-induced TF activity and expression, and down-regulate NF-kappaB, Akt and MAPK/JNK/p38/ERK pathways. Berberine 33-42 mitogen-activated protein kinase 1 Homo sapiens 147-150 24184483-8 2013 However, at 10 mug/mL, berberine reduces cell growth in ADPKD cystic cells only enhancing G0/G1 phase of cell cycle and inhibiting ERK and p70-S6 kinases. Berberine 23-32 mitogen-activated protein kinase 1 Homo sapiens 131-134 22120676-0 2012 Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 103-106 22120676-8 2012 Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation. Berberine 13-22 mitogen-activated protein kinase 1 Homo sapiens 98-101 22120676-8 2012 Furthermore, berberine inhibited the metastatic potential of melanoma cells through a decrease in ERK activity and protein levels of cyclooxygenase-2 (COX-2) by a berberine-induced AMPK activation. Berberine 163-172 mitogen-activated protein kinase 1 Homo sapiens 98-101 22120676-12 2012 Collectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of tumor cells through a reduction in the activity of the ERK signaling pathway and COX-2 protein levels. Berberine 39-48 mitogen-activated protein kinase 1 Homo sapiens 165-168 21527846-11 2011 Our results indicate that inhibition of B-RAF/ERK survival signaling facilitates the cell death response triggered by berberine. Berberine 118-127 mitogen-activated protein kinase 1 Homo sapiens 46-49 21738655-6 2011 Moreover, berberine could significantly inhibit the activity of PI3K-AKT and ERK pathways. Berberine 10-19 mitogen-activated protein kinase 1 Homo sapiens 77-80 21738655-7 2011 Combination treatment of ERK pathway inhibitor PD98059 or AKT pathway inhibitor LY294002 and berberine could result in a synergistic reduction on MMP-9 expression along with an inhibition of cell invasion. Berberine 93-102 mitogen-activated protein kinase 1 Homo sapiens 25-28 21738655-9 2011 In conclusion, our results suggest that berberine may be a potential alternative against invasive hepatoma cells through PI3K-AKT and ERK pathways-dependent downregulation of MMP-9 expression. Berberine 40-49 mitogen-activated protein kinase 1 Homo sapiens 134-137 24278513-6 2010 Bax, caspase-3, p53, p38, and JNK activation increased, but activation of Bcl-2, ERK, and HO-1 decreased with berberine treatment with or without irradiation. Berberine 110-119 mitogen-activated protein kinase 1 Homo sapiens 81-84 17951041-5 2008 Berberine prevented TPA-induced ERK activation and AP-1 DNA binding activity. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 32-35 33959010-10 2021 Accordingly, exposure to berberine markedly upregulated miR150-5p, decreased P2X7R expression and downregulated MMP-9 and EMMPRIN levels in oxLDL-induced macrophages, resulting in AMPK-alpha/MAPK (JNK, p38, and ERK) inactivation. Berberine 25-34 mitogen-activated protein kinase 1 Homo sapiens 211-214 34860319-8 2022 In addition, BBR significantly enhanced ERK as well as both pro- and anti-inflammatory cytokine expression compared to untreated controls. Berberine 13-16 mitogen-activated protein kinase 1 Homo sapiens 40-43 34358871-7 2021 Moreover, we found that BBR significantly reduced the DON-induced gene and protein expression levels of ERK, JNK, and NF-kappaB in the jejunum and ileum. Berberine 24-27 mitogen-activated protein kinase 1 Homo sapiens 104-107 17767919-1 2007 Berberine, an herbal alkaloid, has been reported to have a lipid lowering effect by stabilizing hepatic LDLR mRNA in an ERK-dependent manner rather than promoting transcriptional activity. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 120-123 16100034-0 2005 Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Berberine 130-139 mitogen-activated protein kinase 1 Homo sapiens 0-37 32245183-0 2020 Berberine Hampers Influenza A Replication through Inhibition of MAPK/ERK Pathway. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 69-72 32454290-7 2020 Mechanistic studies showed that berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy. Berberine 32-41 mitogen-activated protein kinase 1 Homo sapiens 72-75 32969153-5 2020 The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/beta-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction. Berberine 113-122 mitogen-activated protein kinase 1 Homo sapiens 276-279 30061836-0 2018 Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 89-126 31781264-0 2019 Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA1. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 97-100 31781264-0 2019 Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA1. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 101-105 31781264-7 2019 Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 172-175 31781264-8 2019 In addition, berberine inhibited the LPA-induced p-38/ERK-phosphorylation through binding to LPA1. Berberine 13-22 mitogen-activated protein kinase 1 Homo sapiens 54-57 31781264-10 2019 Berberine potentially modulates LPA function to suppress the proliferation and inflammation of FLS-RA through blocking the p38/ERK MAPK pathway mediated by LPA1. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 127-130 31781264-10 2019 Berberine potentially modulates LPA function to suppress the proliferation and inflammation of FLS-RA through blocking the p38/ERK MAPK pathway mediated by LPA1. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 131-135 30502647-8 2019 In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter. Berberine 77-86 mitogen-activated protein kinase 1 Homo sapiens 144-147 30502647-8 2019 In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter. Berberine 77-86 mitogen-activated protein kinase 1 Homo sapiens 190-227 30502647-8 2019 In addition, the possible molecular mechanism of anti-inflammation effect of berberine could be the inhibition of PHA-evoked phosphorylation of p38, since c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinase (ERK) expressions did not alter. Berberine 77-86 mitogen-activated protein kinase 1 Homo sapiens 229-232 30502647-9 2019 Consistent with above results, berberine inhibition on PHA-induced IL-2 secretion could be reversed by treatment of SB203580, a specific inhibitor of p38-MAPK. Berberine 31-40 mitogen-activated protein kinase 1 Homo sapiens 150-153 30502647-12 2019 In conclusion, our study demonstrated that the anti-inflammatory effect of berberine largely potentially results from its ability to attenuate p38 MAPK expression, and does not exclude a positive action of berberine on cell cycle arrest. Berberine 75-84 mitogen-activated protein kinase 1 Homo sapiens 143-146 30466991-0 2018 Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 76-79 30343043-0 2019 Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. Berberine 21-30 mitogen-activated protein kinase 1 Homo sapiens 53-56 30343043-6 2019 RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability. Berberine 28-37 mitogen-activated protein kinase 1 Homo sapiens 76-79 30343043-6 2019 RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability. Berberine 28-37 mitogen-activated protein kinase 1 Homo sapiens 266-269 30343043-9 2019 The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation. Berberine 60-69 mitogen-activated protein kinase 1 Homo sapiens 27-30 31070539-0 2018 Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 83-86 31070539-10 2018 Berberine inhibited (p 0.001) the phosphorylation of VEGFR2 and ERK. Berberine 0-9 mitogen-activated protein kinase 1 Homo sapiens 66-69 31070539-11 2018 DISCUSSION AND CONCLUSIONS: Berberine inhibited angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway. Berberine 28-37 mitogen-activated protein kinase 1 Homo sapiens 112-115 30087941-0 2018 Drug-Carrying Capacity and Anticancer Effect of the Folic Acid- and Berberine-Loaded Silver Nanomaterial To Regulate the AKT-ERK Pathway in Breast Cancer. Berberine 68-77 mitogen-activated protein kinase 1 Homo sapiens 125-128 29079630-0 2017 ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. Berberine 42-51 mitogen-activated protein kinase 1 Homo sapiens 0-3 27092498-6 2016 Furthermore, berberine inactivated p38 and Erk1/2 signaling pathway in HCC cells. Berberine 13-22 mitogen-activated protein kinase 1 Homo sapiens 35-38 26672764-8 2016 Melatonin also increased the berberine-mediated inhibition of the phosphorylated Akt and ERK. Berberine 29-38 mitogen-activated protein kinase 1 Homo sapiens 89-92 26672764-9 2016 Collectively, our results demonstrated that melatonin enhanced the antitumor activity of berberine by activating caspase/Cyto C and inhibiting AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK signaling pathways. Berberine 89-98 mitogen-activated protein kinase 1 Homo sapiens 183-186 26503508-9 2015 Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration. Berberine 247-256 mitogen-activated protein kinase 1 Homo sapiens 84-87 26503508-9 2015 Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration. Berberine 304-313 mitogen-activated protein kinase 1 Homo sapiens 84-87 29434321-0 2018 The promotion function of Berberine for osteogenic differentiation of human periodontal ligament stem cells via ERK-FOS pathway mediated by EGFR. Berberine 26-35 mitogen-activated protein kinase 1 Homo sapiens 112-115 26672764-0 2016 Melatonin inhibits AP-2beta/hTERT, NF-kappaB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells. Berberine 139-148 mitogen-activated protein kinase 1 Homo sapiens 59-62